Pulmocide

About:

Pulmocide is focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.

Website: http://www.pulmocide.com

Top Investors: F-Prime Capital, IP Group, SV Health Investors, Jeito Capital, Longwood Fund

Description:

Pulmocide Ltd, a company focused on the discovery and development of a new generation of inhaled medicines for the treatment of serious viral and fungal infections of the respiratory tract.

Total Funding Amount:

$205M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

London, England, United Kingdom

Founded Date:

2013-01-01

Contact Email:

admin(AT)pulmocide.com

Founders:

Garth Rapeport, Pete Strong

Number of Employees:

11-50

Last Funding Date:

2022-12-06

IPO Status:

Private

Industries: